← All organizations
Highest phase reached
Phase 4
First clinical trial
May 1, 2008Last known activity
Sep 23, 2025
Timeline
1880s
- Jan 1, 1883
Shengjing Hospital— Founded
Drugs by trial phase (118 distinct, 96 trials)
Phase 4 (44 own, 0 via acquisition)
Phase 3 (31 own, 0 via acquisition)
Phase 2 (30 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Other trials (12 own, 0 via acquisition)
Indications
Studied for
- Acute Kidney Injury
- Adenocarcinoma
- Anemia
- Anemia, Aplastic
- Anovulation
- Anxiety Disorders
- Bacterial Infections
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Disseminated Intravascular Coagulation
- Dwarfism
- Endocarditis
- Flushing
- Gallbladder Neoplasms
- Heart Failure
- Heart Failure, Systolic
- Hemophilia A
- Hypertension
- Hypertension, Pulmonary
- Infections
- Infertility
- Kidney Diseases
- Lung Neoplasms
- Memory Disorders
- Nausea
- Postoperative Complications
- Rectal Neoplasms
- Renal Insufficiency, Chronic
- Sepsis
- Tachycardia
- Toxemia
- Triple Negative Breast Neoplasms
- Uterine Cervical Neoplasms
- Vomiting
- Wilms Tumor
Recent trials (50)
- NCT07232290OfficialPhase 2Sep 23, 2025
- NCT07101614Lead sponsorPhase 2Sep 1, 2025
- NCT07101614Sponsor investigatorPhase 2Sep 1, 2025
- NCT06941766CollaboratorPhase 1/Phase 2Apr 15, 2025
- NCT06820762OfficialPhase 2Feb 28, 2025
- NCT06820762CollaboratorPhase 2Feb 28, 2025
- NCT06549855CollaboratorN/AOct 31, 2024
- NCT06288360CollaboratorPhase 2Sep 12, 2024
- NCT06289751CollaboratorPhase 2Sep 3, 2024
- NCT06340230OfficialPhase 2Aug 23, 2024
- NCT06340230Lead sponsorPhase 2Aug 23, 2024
- NCT06340230Sponsor investigatorPhase 2Aug 23, 2024
- NCT06512519CollaboratorN/AJul 1, 2024
- NCT06472232CollaboratorPhase 4Jun 18, 2024
- NCT06289062CollaboratorPhase 2May 8, 2024
Details
- Founded
- Shenyang, CN Jan 1, 1883
- Last known activity
- Sep 23, 2025